Literature DB >> 3409441

Flavone acetic acid: a nonlinear pharmacokinetic model.

A Gouyette1, D J Kerr, S B Kaye, A Setanoians, J Cassidy, C Bradley, G Forrest, M Soukop.   

Abstract

Flavone acetic acid pharmacokinetics were studied in 31 patients in a phase I clinical trial. The drug was given by i.v. infusions over 1, 1.5, 3, and 6 h at doses ranging from 0.5 to 6.4 g/m2. The pharmacokinetic parameters were determined according to a nonlinear model including Michaelis-Menten-type kinetics. The mean elimination half-life is 4.8 h and the mean volume of distribution of the central compartment, 7.61. Our model predicted a maximal tolerated dose (MTD) of 11.1 g/m2 on the basis of the "therapeutic window" concept, very close to the clinically observed MTD of 10 g/m2. This model is also operational when different protocols of inoculation are considered, such as a divided-dose schedule vs a unique infusion, and indicates that, at the MTD, injections should be made every 72 h to avoid drug accumulation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3409441     DOI: 10.1007/bf00257307

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  14 in total

1.  Pharmacokinetics of intra-arterial and intravenous cisplatin in head and neck cancer patients.

Authors:  A Gouyette; A Apchin; M Foka; J M Richard
Journal:  Eur J Cancer Clin Oncol       Date:  1986-03

2.  Evidence of possible dose-dependent doxorubicin plasma kinetics in man.

Authors:  R C Boston; D R Phillips
Journal:  Cancer Treat Rep       Date:  1983-01

3.  A program package for simulation and parameter estimation in pharmacokinetic systems.

Authors:  D Z D'Argenio; A Schumitzky
Journal:  Comput Programs Biomed       Date:  1979-03

4.  Pharmacokinetics: statistical moment calculations.

Authors:  A Gouyette
Journal:  Arzneimittelforschung       Date:  1983

5.  Theoretical Michaelis-Menten elimination model for propranolol.

Authors:  J McAinsh; M A Gay
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1985 Jul-Sep       Impact factor: 2.441

6.  Therapeutic and pharmacokinetic relationships of flavone acetic acid: an agent with activity against solid tumors.

Authors:  D S Zaharko; C K Grieshaber; J Plowman; J C Cradock
Journal:  Cancer Treat Rep       Date:  1986-12

7.  Activity of flavone acetic acid (NSC-347512) against solid tumors of mice.

Authors:  T H Corbett; M C Bissery; A Wozniak; J Plowman; L Polin; E Tapazoglou; J Dieckman; F Valeriote
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

8.  Preliminary phase I clinical study and pharmacokinetics of (1,2-diaminocyclohexane) (isocitrato) platinum (II) or PHIC.

Authors:  A Gouyette; J P Ducret; P Caillé; J L Amiel; J Rouëssé; M Foka; P Carde; M Hayat; H Sancho-Garnier
Journal:  Anticancer Res       Date:  1986 Sep-Oct       Impact factor: 2.480

9.  Phase I and pharmacokinetic study of LM985 (flavone acetic acid ester).

Authors:  D J Kerr; S B Kaye; J Graham; J Cassidy; M Harding; A Setanoians; J C McGrath; W R Vezin; D Cunningham; G Forrest
Journal:  Cancer Res       Date:  1986-06       Impact factor: 12.701

10.  Pharmacokinetics of 2-methyl-9-hydroxyellipticinium acetate (NSC-264137) in cancer patients (phase I study).

Authors:  A Gouyette; D Huertas; J P Droz; J Rouesse; J L Amiel
Journal:  Eur J Cancer Clin Oncol       Date:  1982-12
View more
  9 in total

1.  Mathematical analysis and drug exposure evaluation of pharmacokinetic models with endogenous production and simultaneous first-order and Michaelis-Menten elimination: the case of single dose.

Authors:  Xiaotian Wu; Fahima Nekka; Jun Li
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-07-09       Impact factor: 2.745

2.  Flavone acetic acid and plasma protein binding.

Authors:  J Brodfuehrer; F Valeriote; K Chan; L Heilbrun; T Corbett
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  A phase I and pharmacokinetic study of 12-h infusion of flavone acetic acid.

Authors:  I N Olver; L K Webster; J F Bishop; K H Stokes
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Phase I and pharmacology study of flavone acetic acid administered two or three times weekly without alkalinization.

Authors:  M de Forni; G G Chabot; J P Armand; A Gouyette; M Klink-Alak; G Recondo
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

5.  Plasma pharmacokinetics of the antitumour agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in mice.

Authors:  M J McKeage; P Kestell; W A Denny; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

6.  Flavone acetic acid (LM-975; NSC-347512) activation to cytotoxic species in vivo and in vitro.

Authors:  G G Chabot; M C Bissery; A Gouyette
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

7.  Flavone acetic acid distribution in human malignant tumors.

Authors:  G Damia; A Freschi; R Sorio; A Braida; G Caruso; M Quaia; S Monfardini; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

8.  Saturable elimination and saturable protein binding account for flavone acetic acid pharmacokinetics.

Authors:  M V Relling; R R Evans; S Groom; W R Crom; C B Pratt
Journal:  J Pharmacokinet Biopharm       Date:  1993-12

9.  Tumour concentrations of flavone acetic acid (FAA) in human melanoma: comparison with mouse data.

Authors:  T S Maughan; R Ward; I Dennis; D J Honess; P Workman; N M Bleehen
Journal:  Br J Cancer       Date:  1992-09       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.